Key Highlights
- Jan Malcolm, former Minnesota Commissioner of Health, joins United Therapeutics’ Board of Directors.
- Election by Shareholders: Ms. Malcolm was elected at the annual meeting on June 26, 2024.
- Expertise in Public Health: Renowned for her leadership in health policy and public health.
- Innovative Mission: Supports efforts to develop and distribute manufactured organs.
Source: Business Wire
Notable Quotes
- “We greatly value Ms. Malcolm’s deep healthcare operational experience, as well as her leadership experience in public health and government. We believe her unique qualifications will support our efforts to revolutionize the treatment of end-stage organ disease through the development, commercialization, and distribution of manufactured organs.” — Martine Rothblatt, Ph.D., Chairperson and CEO at United Therapeutics
- “I am proud to add Ms. Malcolm’s voice to our boardroom. Her nomination is an important step in our efforts to refresh our Board, which are focused on bringing in new skill sets to pursue our patient-centric public benefit purpose and address the severe shortage of transplantable organs.” — Christopher Causey, Chairman of the Nominating and Governance Committee at United Therapeutics Board of Directors
- “On behalf of the entire Board, I want to thank Professor Klein for her decade of service. During her tenure, she helped oversee a period of exciting growth for our company as we laid the foundation for our revolutionary organ manufacturing programs.” — Christopher Patusky, Lead Independent Director and Vice Chair at United Therapeutics Board of Directors
- “It’s an honor to support United Therapeutics’ unique mission to address critical unmet medical needs of patients. I look forward to working with the Board and senior management, which collectively bring together the skills needed to make a difference for patients with rare lung diseases and other end-stage organ diseases.” — Jan Malcolm, Former Commissioner of Health at Minnesota
SoHC's Take
The addition of Jan Malcolm to the United Therapeutics Board of Directors marks a significant step forward in the company’s mission to innovate and expand the availability of transplantable organs. Ms. Malcolm’s extensive background in public health and her leadership during the COVID-19 pandemic exemplify her capability to contribute effectively to United Therapeutics’ pioneering initiatives. Her strategic insights and operational expertise are expected to bolster the company’s efforts in revolutionizing treatments for end-stage organ diseases, aligning perfectly with its public benefit purpose. This move underscores United Therapeutics’ commitment to addressing the severe shortage of transplantable organs, promising a brighter future for patients.
